Search
Coauthors
John Bell Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Canada
1 protocol

Laura Evgin
  • Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Canada
  • 1 Author merit

Education

Ph.D., University of Ottawa, Canada

Current position

Post-doctoral fellow, Mayo Clinic, Minnesota, USA

Publications

  1. Evgin, L., Acuna, S. A., Tanese de Souza, C., Marguerie, M., Lemay, C. G., Ilkow, C. S., Findlay, C. S., Falls, T., Parato, K. A., Hanwell, D., Goldstein, A., Lopez, R., Lafrance, S., Breitbach, C. J., Kirn, D., Atkins, H., Auer, R. C., Thurman, J. M., Stahl, G. L., Lambris, J. D., Bell, J. C. and McCart, J. A. (2015). Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther 23(6): 1066-1076.
  2. Muharemagic, D., Zamay, A., Ghobadloo, S. M., Evgin, L., Savitskaya, A., Bell, J. C. and Berezovski, M. V. (2014). Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies. Mol Ther Nucleic Acids 3: e167.
  3. Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J. S., Falls, T., Burns, J., Garcia, V., Kanji, F., Evgin, L., Hu, K., Paradis, F., Knowles, S., Hwang, T. H., Vanderhyden, B. C., Auer, R., Kirn, D. H. and Bell, J. C. (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20(4): 749-758.
  4. Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q., Nieva, J., Hwang, T. H., Moon, A., Patt, R., Pelusio, A., Le Boeuf, F., Burns, J., Evgin, L., De Silva, N., Cvancic, S., Robertson, T., Je, J. E., Lee, Y. S., Parato, K., Diallo, J. S., Fenster, A., Daneshmand, M., Bell, J. C. and Kirn, D. H. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362): 99-102.
  5. Breitbach, C. J., De Silva, N. S., Falls, T. J., Aladl, U., Evgin, L., Paterson, J., Sun, Y. Y., Roy, D. G., Rintoul, J. L., Daneshmand, M., Parato, K., Stanford, M. M., Lichty, B. D., Fenster, A., Kirn, D., Atkins, H. and Bell, J. C. (2011). Targeting tumor vasculature with an oncolytic virus. Mol Ther 19(5): 886-894.
  6. Evgin, L., Vaha-Koskela, M., Rintoul, J., Falls, T., Le Boeuf, F., Barrett, J. W., Bell, J. C. and Stanford, M. M. (2010). Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 18(5): 896-902.
1 Protocol published
Human Blood Component Vaccinia Virus Neutralization Assay
Authors:  Laura Evgin and John Bell, date: 12/05/2015, view: 2480, Q&A: 0
Many therapeutic viruses, such as oncolytic viruses, vaccines, or gene therapy vectors, may be administered by the intravenous route to maximize their delivery to target tissues. Blood components, such as antibody, complement and blood cells (such ...